Phase II study of combination chemotherapy with S-1 and weekly cisplatin in patients with previously untreated advanced non-small cell lung cancer

Lung Cancer

Volumn 63, Issue 1, 2009, Pages 68-71

  Ozawa, Yuichi ^a   Inui, Naoki ^a   Naitoh, Tateaki ^a   Yasuda, Kazumasa ^a   Nagayama, Masaharu ^a   Shirai, Toshihiro ^a   Suganuma, Hideki ^a   Fujii, Masato ^a   Nakamura, Hirotoshi ^a   Suda, Takafumi ^a   Chida, Kingo ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin; Dosage regimen; Non small cell lung cancer; Outpatient; Phase II study; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MALE; MEDICAL ASSESSMENT; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OUTPATIENT DEPARTMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SKIN PIGMENTATION; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OXONIC ACID; TEGAFUR; TIME FACTORS; TREATMENT OUTCOME;

EID: 57649086794     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.04.007     Document Type: Article

References (16)

1. Greenlee R.T., Murray T., Bolden S., and Wingo P.A. Cancer statistics, 2000. CA Cancer J Clin 50 (2000) 7-33
2. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
3. Shirasaka T., Shimamato Y., Ohshimo H., Yamaguchi M., Kato T., Yonekura K., et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7 (1996) 548-557
4. van Groeningen C.J., Peters G.J., Schornagel J.H., Gall H., Noordhuis P., de Vries M.J., et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 18 (2000) 2772-2779
5. Yamada Y., Hamaguchi T., Goto M., Muro K., Matsumura Y., Shimada Y., et al. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. Br J Cancer 89 (2003) 816-820
6. Kawahara M., Furuse K., Segawa Y., Yoshimori K., Matsui K., Kudoh S., et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85 (2001) 939-943
7. Kaida Y., Inui N., Suda T., Nakamura H., Watanabe H., and Chida K. The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer. Clin Pharmacol Ther 83 (2008) 589-594
8. Shirasaka T., Shimamoto Y., Ohshimo H., Saito H., and Fukushima M. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 32 (1993) 167-172
9. Scanlon K.J., Newman E.M., Lu Y., and Priest D.G. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83 (1986) 8923-8925
10. Ichinose Y., Yoshimori K., Sakai H., Nakai Y., Sugiura T., Kawahara M., et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 10 (2004) 7860-7864
11. Kelly K., Crowley J., Bunn Jr. P.A., Presant C.A., Grevstad P.K., Moinpour C.M., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19 (2001) 3210-3218
12. Niho S., Ohe Y., Kakinuma R., Kubota K., Matsumoto T., Ohmatsu H., et al. Phase II study of docetaxel and cisplatin administered as three consecutive weekly infusions for advanced non-small cell lung cancer. Lung Cancer 35 (2002) 209-214
13. Nakata B., Mitachi Y., Tsuji A., Yamamitsu S., Hirata K., Shirasaka T., et al. Combination phase I trial of a novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902). Clin Cancer Res 10 (2004) 1664-1669
14. Ohe Y., Niho S., Kakinuma R., Kubota K., Ohmatsu H., Goto K., et al. A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. Ann Oncol 15 (2004) 45-50
15. Hyodo I., Nishina T., Moriwaki T., Endo S., Terao T., Hirao K., et al. A phase I study of S-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient setting. Eur J Cancer 39 (2003) 2328-2333
16. Kondo K., Kinoshita M., Kataoka M., Shimoyama S., Yamamura K., Ohshima Y., et al. A phase I study of TS-1 and weekly cisplatin in patients with advanced gastric cancer. Gan To Kagaku Ryoho 32 (2005) 637-639